Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsGreg Rhee, PhD, FACE
Associate Professor Adjunct in PsychiatryDownloadHi-Res Photo
About
Copy Link
Titles
Associate Professor Adjunct in Psychiatry
Biography
Greg Rhee, PhD, FACE, is Associate Professor of Medicine (Psychiatry) and Public Health (Epidemiology and Biostatistics). He is a pharmaco-epidemiologist and mental health services researcher studying access to care, quality of care, and clinical and patient-reported outcomes in patients with psychiatric and/or substance use disorders. His current research focuses on mood disorders, dementias, and suicide/suicidal behaviors as well as cannabis and opioids.
As an accredited professional statistician (PStat®) certified by the American Statistical Association, his expertise is grounded in (1) population-based observational studies using large databases; (2) systematic reviews and meta-analyses of existing studies; and (3) analyses of clinical trial data. In particular, he has extensive knowledge and experience with administrative claims data (e.g., Medicare and Medicaid), national health and healthcare survey data, and other data sources including electronic health records (e.g., Epic® database from Yale-New Haven Health), RCT data, and mortality data. He also investigates long-term comparative effectiveness and cost-effectiveness of pharmacological and non-pharmacological interventions for psychiatric and/or substance use disorders.
He has 250+ peer-reviewed research articles published in highly respected medical, psychiatric, and healthcare policy journals, such as Lancet, Lancet Neurology, JAMA, JAMA Psychiatry, and American Journal of Psychiatry. He has also been a successful Principal Investigator or Co-Investigator on multiple research projects funded by federal agencies, including Agency for Healthcare Research and Quality (AHRQ), Food and Drug Administration (FDA), and National Institutes of Health (NIH).
Outside Yale Psychiatry, he also serves as an Investigator at the VA Connecticut Healthcare System VISN 1 MIRECC and as a Senior Investigator at the Institute for Health Metrics and Evaluation (IHME).
Last Updated on March 22, 2025.
Departments & Organizations
Education & Training
- NIH Postdoctoral Fellowship
- Yale University School of Medicine (2019)
- PhD
- University of Minnesota, Twin Cities (2017)
- MA
- The University of Chicago (2011)
- AB
- Emory University (2008)
Research
Copy Link
Overview
Medical Research Interests
Delivery of Health Care; Epidemiologic Methods; Geriatric Psychiatry; Health Services Research; Mental Disorders; Meta-Analysis; Network Meta-Analysis; Population Surveillance; Psychotropic Drugs; Substance-Related Disorders; United States Food and Drug Administration
Public Health Interests
Mental Health; Health Policy; Health Equity, Disparities, Social Determinants and Justice; Aging; Pharmaceuticals and Medical Devices
ORCID
0000-0003-4961-3361
Research at a Glance
Yale Co-Authors
Frequent collaborators of Greg Rhee's published research.
Publications Timeline
A big-picture view of Greg Rhee's research output by year.
Research Interests
Research topics Greg Rhee is interested in exploring.
Samuel Wilkinson, MD
Joseph Ross, MD, MHS
Robert Rosenheck, MD
John Havlik, MD, MBA
Gerard Sanacora, PhD, MD
Sina Nikayin, MD
167Publications
4,311Citations
Substance-Related Disorders
Mental Disorders
Psychotropic Drugs
United States Food and Drug Administration
Delivery of Health Care
Publications
2026
Metabolic dysfunction-associated steatotic liver disease and neurocognitive and reward circuit dysfunction: implications for mental disorders
Mollin N, Le G, Dri C, Yang E, van Bruggen F, Lin K, Bargiota S, Lo H, Ho R, Rhee T, Cao B, Kwan A, McIntyre R. Metabolic dysfunction-associated steatotic liver disease and neurocognitive and reward circuit dysfunction: implications for mental disorders. CNS Spectrums 2026, 31: e17. DOI: 10.1017/s1092852926100984.Peer-Reviewed Original ResearchAltmetricConceptsBrain alterationsReward-related brain functionAssociated with poorer attentionReward-related processesReward circuit dysfunctionFunctional brain alterationsAssociated with cognitive impairmentWhite matter volumeReward outcomesExecutive functionNeuroimaging studiesVisuospatial regionsMatter volumeCircuit dysfunctionNeuropsychiatric riskMental disordersCognitive functionPoor attentionNeural systemsWhite matter hyperintensitiesBrain healthBrain functionCognitive impairmentCortical thicknessRewardKetamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode
Shim S, Jeong H, Bommersbach T, Nierenberg A, Zarate C, Kaster T, Correll C, McIntyre R, Krystal J, Rhee T. Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode. JAMA Psychiatry 2026, 83 PMID: 42090166, PMCID: PMC13150733, DOI: 10.1001/jamapsychiatry.2026.0612.Peer-Reviewed Original ResearchCitationsAltmetricConceptsDepressive symptomsKetamine infusionRandomized clinical trialsSuicidal symptomsDepressive episodeIntravenous ketamineMajor depressive episodeRemission rateRates of depressive symptomsReduction of suicideAdverse eventsIntravenous ketamine infusionUS Food and Drug AdministrationHedges g standardized mean differencesSerious adverse eventsOff-label indicationsFood and Drug AdministrationMultiple subgroup analysesRandom-effects modelSuicideMDELonger-term outcomesEfficacy outcomesControl patientsKetamineAdjunctive Antipsychotics in Major Depressive Disorder
McIntyre R, Stahl S, Shim S, Pompili M, Goldberg J, Correll C, Kwan A, Dri C, Xu H, Vinberg M, Rhee T. Adjunctive Antipsychotics in Major Depressive Disorder. JAMA Psychiatry 2026, 83 PMID: 42090141, PMCID: PMC13150735, DOI: 10.1001/jamapsychiatry.2026.0658.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAdjunctive atypical antipsychoticsTreatment of MDDAtypical antipsychoticsQuetiapine XRDepressive disorderMaintenance efficacyAdjunctive treatmentAdjunctive treatment of MDDFDA-approved atypical antipsychoticEffect sizeMajor depressive disorderFood and Drug AdministrationHighest effect sizeAdjunctive antipsychoticsAntipsychoticsMDDEvidence of efficacyCariprazineLumateperoneAripiprazoleQuetiapineBrexpiprazoleUS Food and Drug AdministrationRatersDisordersCognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial.
Wilkinson S, Kitay B, Macaluso M, Santucci M, Kumpf K, Voghell C, Astorino L, Hershenberg R, Martinez-Kaigi V, Nowell T, Thase M, Sanacora G, Rhee T. Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial. The Journal Of Clinical Psychiatry 2026, 87 PMID: 42095692, DOI: 10.4088/jcp.25m16285.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsCognitive behavioral therapyBeck Scale for Suicide IdeationSuicidal ideationBehavioral therapyCourse of CBTColumbia-Suicide Severity Rating Scale scoresMontgomery-Asberg Depression Rating ScaleAdjunctive cognitive behavioral therapyScale for Suicide IdeationCognitive behavioral therapy groupDepression Rating ScaleTreatment-seeking patientsGlobal Improvement ScaleSuicide-related eventsDose of esketamineRating Scale scoresStudy completion ratesMontgomery-AsbergSuicide severityDepressive disorderMajor depressionRelapse preventionTAU groupEsketamineAttainment of skillsConcurrent SSRI, SNRI, or Other Antidepressant Use Not Associated With Differential Outcomes in Ketamine or Esketamine Treatment.
Curran E, Hardy M, Katz R, Rhee T, Wilkinson S. Concurrent SSRI, SNRI, or Other Antidepressant Use Not Associated With Differential Outcomes in Ketamine or Esketamine Treatment. The Journal Of Clinical Psychiatry 2026, 87 PMID: 42095696, DOI: 10.4088/jcp.25br16294.Peer-Reviewed Original ResearchAltmetricElectroconvulsive therapy: improved understanding of long-term risks and benefits from advances in administrative health data
Kaster T, Rhee T, Adler E, Kirov G. Electroconvulsive therapy: improved understanding of long-term risks and benefits from advances in administrative health data. The British Journal Of Psychiatry 2026, 1-6. PMID: 41986911, PMCID: PMC13173538, DOI: 10.1192/bjp.2026.10613.Peer-Reviewed Original ResearchAltmetricConceptsAdministrative health dataHealth dataObservational studyRisk of dementiaCardiovascular/cerebrovascular eventsElectroconvulsive therapyAll-Cause MortalitySuicide mortalityLong-term riskLong-term outcomesSuicide deathsSuperiority of ECTPsychiatric illnessTreatment-resistant psychiatric illnessAdverse cardiovascular/cerebrovascular eventsLife-saving treatmentClinically relevant questionsDementiaClinical trialsSymptom reductionConfoundingTraditional clinical trialsNeuroimaging studiesMortalityRiskInsufficient Sleep Among US Adolescents Across Behavioral Risk Groups
Bommersbach T, Olfson M, Rhee T. Insufficient Sleep Among US Adolescents Across Behavioral Risk Groups. JAMA: The Journal Of The American Medical Association 2026, 335: 1173-1176. PMID: 41770537, PMCID: PMC12954592, DOI: 10.1001/jama.2026.1417.Peer-Reviewed Original ResearchCitationsAltmetricConceptsClinical effects of ursodeoxycholic acid in COVID-19 infection: a systematic review and dose–response meta-analysis
Song J, Shim S, Shin J, Choe W, Park J, Lee T, Kang S, Rhee T, Huh K. Clinical effects of ursodeoxycholic acid in COVID-19 infection: a systematic review and dose–response meta-analysis. Frontiers In Pharmacology 2026, 17: 1719144. PMID: 41993579, PMCID: PMC13079291, DOI: 10.3389/fphar.2026.1719144.Peer-Reviewed Original ResearchCitationsConceptsEffect of ursodeoxycholic acidDose-response meta-analysisUrsodeoxycholic acid groupCOVID-19 infectionUrsodeoxycholic acidNon-randomized studiesClinical effectsVentilator useStandardized mean differenceRisk of biasDosage of ursodeoxycholic acidOdds ratioLow riskInfection riskMortality rateIntensive care unit hospitalizationMeta-analysisSystematic reviewNon-randomized Studies of InterventionsDose-response associationFarnesoid X receptor activationLow risk of infectionInfection rateStudies of interventionsLevel of risk of biasCalculating and extracting missing summary statistics for meta-analysis
Shin J, Rhee T, Kim S, Shim S. Calculating and extracting missing summary statistics for meta-analysis. Journal Of Evidence-Based Practice 2026, 2: 1-7. DOI: 10.63528/jebp.2026.00002.Peer-Reviewed Original ResearchConceptsMeta-analysisEffect sizeEvidence-based decision-makingRisk estimatesHazard ratioSystematic reviewMeta-analysesMeasures of varianceFrequency tablesSelection biasStatistical powerStandard errorContinuous dataMedical literatureCategorical dataKaplan-Meier survival curvesDecision-makingData inclusionRobust synthesisStatisticallyGraphError adjustmentSDVarianceMedically Recommended Cannabis Use for U.S. Adolescents
Bommersbach T, Olfson M, Rhee T. Medically Recommended Cannabis Use for U.S. Adolescents. American Journal Of Preventive Medicine 2026, 71: 108355. PMID: 41903661, DOI: 10.1016/j.amepre.2026.108355.Peer-Reviewed Original ResearchConceptsCannabis use disorderMedical cannabis usePast-year cannabis useCannabis useUse disorderSociodemographic factorsSevere cannabis use disorderSubstance useMultivariable-adjusted logistic regression modelsPrevalence of past-yearNonmedical cannabis useFrequent cannabis useBlack non-HispanicDrug Use and HealthPast-yearLogistic regression modelsCocaine useCross-sectional dataHealthcare professionalsNon-HispanicMedical cannabisNonmedical useNational surveyCannabisU.S. adolescents
Academic Achievements & Community Involvement
Copy Link
Activities
activity Journal of Clinical Psychiatry
06/01/2022 - PresentJournal ServiceEditorial Board Memberactivity Depression and Anxiety
10/01/2022 - PresentJournal ServiceAssociate Editoractivity American Journal of Geriatric Psychiatry
2023 - PresentJournal ServiceEditorial Board Memberactivity National Institutes of Health Center for Scientific Review (CSR) - Study Section
2023 - PresentPeer Review Groups and Grant Study SectionsCommittee Member
Honors
honor Delta Omega Honorary Society in Public Health
05/05/2023International AwardDelta Omega (Faculty Mentor)honor Fellow
10/29/2022International AwardAmerican College of EpidemiologyDetailsUnited Stateshonor NIMH Advanced Research Institute (ARI) in Aging and Mental Health
02/01/2021National AwardNational Institute of Mental HealthDetailsUnited Stateshonor Research Career Institute in Mental Health of Aging (CIMA) Award
06/25/2019National AwardNational Institute of Mental HealthDetailsUnited Stateshonor Travel Fellowship
06/25/2019National AwardAssociation for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA)DetailsUnited States
News
Copy Link
News
- May 06, 2026
CBT After Esketamine Can Prevent Relapses in Patients with Major Depression, Suicidal Ideation
- May 06, 2026Source: JAMA Psychiatry
Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode
- May 06, 2026Source: JAMA Psychiatry
Adjunctive Antipsychotics in Major Depressive Disorder
- March 04, 2026Source: JAMA
Insufficient Sleep Among US Adolescents Across Behavioral Risk Groups
Get In Touch
Copy Link
Contacts
Email